Pfizer Inc
In its 13F for Q1 2025 (holdings as of March 31, 2025, filed May 13, 2025), Pfizer Inc reported 21 stock positions worth $500.8 million. Its top holding was Biontech SE-ADR (BNTX) at 66.5% of the portfolio, followed by Allogene Therapeutics (ALLO, 6.4%) and Oric Pharmaceuticals (ORIC, 6.0%). Compared with Q4 2024, it sold out of 2 and added to 1. The biggest buy was Nextcure (NXTC, shares +30%) and the biggest sale an exit from Haleon PLC-ADR (HLN).
- Most Recent 13F
- Q2 2026
- Location
- New York, NY
- CIK
- 0000078003
- Portfolio Value
- $500.8M (Q1 2025)
- SEC Filing
- 0000078003-25-000118 ↗ filed May 13, 2025
Holdings Value
Holdings 21 stocks · $500.8M
| BNTX Biontech SE-ADR | 66.51% | 3,658,361 | $333.1M | No change |
| ALLO Allogene Therapeutics Inc. | 6.42% | 22,032,040 | $32.2M | No change |
| ORIC Oric Pharmaceuticals Inc. | 5.99% | 5,376,344 | $30.0M | No change |
| ARVN Arvinas Inc. | 4.85% | 3,457,815 | $24.3M | No change |
| TRML Tourmaline Bio Inc. | 3.86% | 1,272,214 | $19.4M | No change |
| WVE Wave Life Sciences Ltd. | 3.02% | 1,875,000 | $15.2M | No change |
| BHVN Biohaven Ltd. | 2.43% | 505,645 | $12.2M | No change |
| CRDF Cardiff Oncology Inc. | 1.51% | 2,411,575 | $7.6M | No change |
| PYXS Pyxis Oncology Inc. | 1.38% | 7,032,770 | $6.9M | No change |
| CRBU Caribou Biosciences Inc. | 0.86% | 4,690,431 | $4.3M | No change |
| ZURA Zura Bio Ltd. | 0.77% | 2,970,022 | $3.8M | No change |
| CELC Celcuity Inc. | 0.71% | 349,406 | $3.5M | No change |
| EPIX Essa Pharma Inc. | 0.53% | 1,675,000 | $2.6M | No change |
| SPRO Spero Therapeutics Inc. | 0.34% | 2,362,348 | $1.7M | No change |
| ZNTL Zentalis Pharmaceuticals Inc. | 0.30% | 953,834 | $1.5M | No change |
| ANTX AN2 Therapeutics Inc. | 0.19% | 715,295 | $973K | No change |
| NXTC Nextcure Inc. | 0.18% | 1,891,763 | $909K | Add +29.7% |
| QTTB Q32 Bio Inc. | 0.09% | 277,777 | $458K | No change |
| BOLT Bolt Biotherapeutics Inc. | 0.05% | 626,109 | $250K | No change |
| SENS Senseonics Holdings Inc. | 0.01% | 43,426 | $28K | No change |
| DNA Ginkgo Bioworks Holdings Inc. | 0.00% | 2,928 | $17K | No change |
Portfolio Sells Q4 2024 → Q1 2025
Portfolio Buys Q4 2024 → Q1 2025
| NXTC Nextcure Inc. | Add +29.7% | 0.18% | +0.11 |
All Filings
| Quarter | Positions | 13F Reported Value | Top Holdings |
|---|---|---|---|
| Q2 2026 | 17 | $170.4M | ALLO, CELC, ARVN, PYXS, WVE |
| Q1 2026 | 18 | $238.8M | ORIC, ALLO, ARVN, CELC, ZURA |
| Q4 2025 | 18 | $236.5M | ORIC, ARVN, CELC, WVE, ALLO |
| Q3 2025 | 21 | $437.5M | BNTX, ORIC, TRML, ARVN, ALLO |
| Q2 2025 | 21 | $576.2M | BNTX, ORIC, ARVN, ALLO, TRML |
| Q1 2025 | 21 | $500.8M | BNTX, ALLO, ORIC, ARVN, TRML |
| Q4 2024 | 23 | $2.6B | HLN, BNTX, ARVN, ALLO, ORIC |